Diamyd Medical
Signal active
Organization
Contact Information
Overview
Diamyd Medical develops the diabetes vaccine Diamyd®, an antigen-specific immunotherapy based on the exclusively licensed GAD-molecule. GABA constitutes alongside with the diabetes vaccine a key asset in Diamyd Medical and the Company uses its GABA in-licensed technology to develop a proprietary GABA drug product.
Diamyd Medical’s shares are traded on Nasdaq Stockholm First North, ticker DMYD B.
About
Industries
Biotechnology
Founded
1994
Employees
1-10
Headquarters locations
Stockholm, Stockholms Lan, Sweden, Europe
Social
Profile Resume
Diamyd Medical headquartered in Europe, operates in the Biotechnology sector. The company focuses on Biotechnology and has secured $248.0M in funding across 16 round(s). With a team of 1-10 employees, Diamyd Medical is actively contributing to advancements in Biotechnology. Their latest funding round, Post-IPO Equity - Diamyd Medical, raised $5.2M. Discover more about their projects, partnerships, and impact on our platform.
Employees
N/A
Funding Rounds
Funding rounds
4
Investors
2
Lead Investors
0
Total Funding Amount
$15.5M
Details
1
Diamyd Medical has raised a total of $15.5M in funding over 1 rounds.
| Announcement date | Transaction name | Number of Investors | Money raised | Lead Investor |
|---|---|---|---|---|
| 2006 | Seed | 100.0K |
Investors
Diamyd Medical is funded by 11 investors.
| Investor Name | Lead Investor | Funding Round | Partners |
|---|---|---|---|
| Bertil Lindkvist | - | FUNDING ROUND - Bertil Lindkvist | 5.2M |
| Anders Essen Möller | - | FUNDING ROUND - Anders Essen Möller | 5.2M |
| Diamyd Medical | - | FUNDING ROUND - Diamyd Medical | 5.2M |
| Bertil Lindkvist | - | FUNDING ROUND - Bertil Lindkvist | 5.2M |
Recent Activity
News
Jul 18, 2024
thefly.com - Diamyd Medical receives second FDA fast track designation for Diamyd
News
Jul 01, 2024
Labiotech.eu - Looking to cure Type 1 diabetes - Beyond Biotech - the podcast from Labiotech
News
Jul 01, 2024
Cision News - Delårsrapport III 23/24 - Diamyd Medical AB
News
May 25, 2024
LinkedIn - Link2Trials on LinkedIn: DIAGNODE-3 clinical trial
News
Apr 24, 2024
Reuters - Diamyd Medical Granted Patent In Japan
Funding Round
Apr 18, 2024
Diamyd Medical raised $5192567 on 2024-04-18 in Post-IPO Equity